MedTrace Logo

The Effects of Mesenchymal Stem Cell Secretome in Rheumatoid Arthritis Patients

NCT05925647 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2023-06-29

No results posted yet for this study

Summary

This research is a clinical trial of administering mesenchymal stem cell secretome to rheumatoid arthritis patients.

Conditions

Interventions

DRUG

Messenchymal stem cell secretome

Mesenchymal stem cell secretome obtained from Kalbe Pharma Company

DRUG

Placebo

NaCl 0,9% infusion

Sponsors & Collaborators

  • Universitas Sebelas Maret

    lead OTHER

Principal Investigators

  • Nurhasan Agung Prabowo, MD · Universitas Sebelas Maret

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-01
Primary Completion
2023-02-28
Completion
2023-03-09

Countries

  • Indonesia

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05925647 on ClinicalTrials.gov